Xuanzhu Biopharmaceutical Co., Ltd. (HKG:2575)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
24.00
-0.60 (-2.44%)
Apr 29, 2026, 4:08 PM HKT
-18.53%
Market Cap 12.43B
Revenue (ttm) 57.61M
Net Income (ttm) -273.20M
Shares Out 517.95M
EPS (ttm) -0.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,207,498
Average Volume 2,370,410
Open 26.00
Previous Close 24.60
Day's Range 23.52 - 26.00
52-Week Range 23.68 - 96.90
Beta n/a
RSI 27.74
Earnings Date Mar 30, 2026

About Xuanzhu Biopharmaceutical

Xuanzhu Biopharmaceutical Co., Ltd. engages in the development, industrialization, and commercialization of small-molecule chemical drugs and macromolecular biopharmaceuticals in China. Its lead product candidates include Core- KBP-3571 for the treatment of duodenum ulcers; XZP-3287, a CDK4/6 inhibitor for the treatment of HR+/HER2 advanced breast cancer; and XZP-3621, a first-line treatment for patients with anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer. The company also develops KM501, a first-in-class HER2/HER2 bisp... [Read more]

Sector Healthcare
Founded 2008
Employees 197
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2575
Full Company Profile

Financial Performance

In 2025, Xuanzhu Biopharmaceutical's revenue was 51.77 million, an increase of 72.03% compared to the previous year's 30.09 million. Losses were -245.51 million, -55.88% less than in 2024.

Financial numbers in CNY Financial Statements

News

There is no news available yet.